NCT06246851

BCG Revaccination Study in Diabetic and Non-Diabetic Adults

Name: Clinical Trial NCT06246851
Creator: University of Oxford
Keywords: Tuberculosis, BCG Danish, biological, clinical trial, United Kingdom

A Clinical Study Comparing the Immune Response to Revaccination With Intradermal BCG and Aerosol BCG in Previously BCG Vaccinated Healthy Adult Volunteers With and Without Type 2 Diabetes

University of Oxford·ClinicalTrials.gov·biologicalRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Tuberculosis
Drug/Device/Intervention: BCG Danish
Study type: Interventional
Intervention type: biological

Sponsor & location

Primary sponsor: University of Oxford
Location: Oxford, United Kingdom

Timeline & enrollment

Phase: N/A
Start date: Feb 01, 2024
End date: Nov 01, 2027
Enrollment: 36 participants

Primary outcome

Intradermal vs. aerosol BCG in non-type 2 diabetics,Intradermal (in type 2 diabetics) vs intradermal (in non-type 2 diabetics)

Summary

The purpose of this study is to:  1. explore whether investigators can make BCG more effective by giving it in a different way. For this, aerosol inhaled BCG will be compared against the conventional BCG injection.  2. explore if there are differences in response to re-vaccination in healthy volunteers with and without Type 2 Diabetes.  It will involve 36 previously BCG-vaccinated participants. Bronchoscopies will be performed 14 days post-challenge to measure BCG recovered from bronchial samples. Blood tests will be taken to look at potential immunological markers of immunity.

ICD-10 classifications

TuberculosisLatent tuberculosisTuberculosis of other organsCongenital tuberculosisSequelae of tuberculosis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06246851
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06246851 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Oxford and is currently Recruiting. The study focuses on Tuberculosis. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.